Drug intelligence / Profile preview

AC105

Development stage: Discontinued
Lead developer: Acorda Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

AC105 is an investigational drug developed for the treatment of acute brain and spinal cord injuries. It is a proprietary magnesium formulation designed to increase extracellular magnesium delivery and reduce excitotoxic glutamate exposure within injured spinal cords, as demonstrated in animal models. The drug received FDA fast track designation in 2009 for use in improving functional recovery after acute spinal cord injury (SCI). AC105 was licensed by Acorda Therapeutics from Medtronic and advanced to Phase II clinical readiness, but there is no evidence of further development or approval since then.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on AC105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC105.

Explore the full profile